Anti-Rheumatic Drugs - Qatar

Qatar

The market of Anti-Rheumatic Drugs market in Qatar is anticipated to witness a substantial growth in revenue, with an estimated projection of US$11.47m in 2024.
Furthermore, it is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of 1.21%, leading to a market volume of US$12.18m by 2029.
When compared globally, United States is forecasted to generate the highest revenue in this market, amounting to a staggering US$34,700.00m in 2024.
Qatar's increasing investment in research and development is driving innovation in the field of Anti-Rheumatic Drugs.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Qatar has been on a steady rise in recent years.

Customer preferences: Patients in Qatar prefer Anti-Rheumatic Drugs that are effective, have minimal side effects, and are affordable. The majority of the population in Qatar is covered under the national health insurance scheme, which makes these drugs more accessible to the general public.

Trends in the market: The Anti-Rheumatic Drugs market in Qatar is expected to grow at a steady pace due to the increasing prevalence of rheumatoid arthritis and other autoimmune diseases. The market is also witnessing the introduction of new and innovative drugs that offer better treatment options for patients. However, the market is also facing challenges such as the high cost of some of these drugs, which can limit their accessibility to the general public.

Local special circumstances: Qatar has a high prevalence of autoimmune diseases, which has led to an increase in the demand for Anti-Rheumatic Drugs. Additionally, the country has a rapidly growing elderly population, who are more susceptible to these diseases.

Underlying macroeconomic factors: The Qatari economy has been growing steadily, which has led to an increase in healthcare spending. The government has also been investing heavily in the healthcare sector, which has led to the development of modern healthcare facilities and an increase in the number of healthcare professionals. These factors have contributed to the growth of the Anti-Rheumatic Drugs market in Qatar.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.